Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Documenti analoghi

• Systematic review of symptom‐level networks of alcohol use disorder
  di: Eve Oostendorp, et al.
  Pubblicazione: (2025)
• Commentary on Aubin et al.: Could combination medication approaches target mental health comorbidity in the context of alcohol use disorder?
  di: Shalini Arunogiri, et al.
  Pubblicazione: (2024)
• 5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
  di: John Marsden, et al.
  Pubblicazione: (2025)
• Psilocybin microdosing in the United States: Insights from a nationally representative survey
  di: Michelle Priest, et al.
  Pubblicazione: (2026)
• Medication effects on cue‐induced craving in the human laboratory are associated with return to heavy drinking in randomized clinical trials for alcohol use disorder: A follow‐up meta‐analysis
  di: Steven J. Nieto, et al.
  Pubblicazione: (2026)